CRO Mass Spectroscopy Services Market (Service Type: Proteomics Services, Metabolomics Services, Others; By End Use: Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global CRO mass spectroscopy services market size was valued at USD 835.17 million in 2023 and is anticipated to reach around USD 4,017.96 million by 2033, expanding at a CAGR of 17.01% from 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. CRO mass spectroscopy services market size reached USD 274.77 million in 2023 and is expected to be worth around USD 1,321.91 million by 2033, poised to grow at a CAGR of 17.09% from 2024 to 2033.
North America led the market with the biggest market share of 46% in 2023., propelled by the widespread adoption of mass spectrometry (MS) technology. MS has revolutionized modern research by offering precise and accurate analysis of various molecules within samples, making it indispensable across industries such as pharmaceuticals, biotechnology, environmental science, and forensics.
In this region, companies and academic institutions are leveraging MS to its full potential, employing the latest technology and techniques to drive innovation in drug development, biomolecular analysis, and scientific research. Notable examples include:
The strong growth of the CRO mass spectroscopy services market in North America is fueled by technological innovations within MS techniques, particularly in LC–MS. These innovations, including triple quadrupole and ion trap technologies, offer high performance and drive demand for MS services, particularly in the life sciences sector. With a concentration of leading research institutions and companies utilizing MS technology effectively, North America remains at the forefront of advancements in mass spectroscopy applications and services.
The CRO mass spectroscopy services market offers techniques and services utilized across diverse scientific domains, including proteomics, metabolomics, pharmaceuticals, environmental, and forensic sciences. It involves the measurement of the mass-to-charge ratio of analyte ions within a sample, enabling the identification, quantification, and structural elucidation of molecules. CRO mass spectrometry services are offered by specialized companies equipped with cutting-edge technology and skilled professionals. These services cater to researchers, industries, and agencies seeking precise analytical solutions. By leveraging mass spectrometry analysis, customers can address scientific inquiries, overcome analytical challenges, and attain their research or business objectives effectively.
Report Coverage | Details |
Growth Rate from 2024 to 2033 | CAGR of 17.01% |
Global Market Size in 2023 | USD 835.17 Million |
Global Market Size by 2033 | USD 4,017.96 Million |
U.S. Market Size in 2023 | USD 274.77 Million |
U.S. Market Size by 2033 | USD 1,321.91 Million |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | Service Type and By End-Use |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver: Integral role in drug development and research
The CRO mass spectrometry services market is experiencing robust growth, primarily driven by its integral role in drug development and research. These services serve as accelerators at every phase of drug R&D, offering invaluable insights that steer drug innovation in the right direction. From target identification to regulatory approval.
Such services play a critical role in ensuring the safety and efficacy of drugs. By delivering accurate and reliable data on drug properties, metabolism, and pharmacokinetics, these services help minimize risks and maximize therapeutic benefits. This assurance of drug safety and efficacy is driving the demand for mass spectrometry services among pharmaceutical companies, the increasing regulatory compliance needs in the pharmaceutical industry are contributing to the growth of the CRO mass spectrometry services market.
Stringent regulatory requirements necessitate extensive testing and analysis throughout the drug development process. Mass spectrometry services offer precise and comprehensive analytical solutions that meet these regulatory standards, making them indispensable for pharmaceutical companies striving to bring safe and effective drugs to market. As regulatory compliance standards continue to evolve, the demand for CRO Mass spectrometry services is expected to further increase, driving market expansion in the foreseeable future.
Restraint: Limitations of mass spectrometry imaging (MSI)
The remarkable capability of mass spectrometry imaging (MSI) to localize panels of biomolecules in tissues without prior knowledge of their presence and in a label-free manner has made a significant impact in clinical and pharmacological research. MSI has been instrumental in uncovering biomolecular changes associated with diseases and providing cost-effective imaging of pharmaceuticals. However, this very capability poses a restraint on the growth of the CRO mass spectroscopy services market. While MSI offers unparalleled insights into tissue biomolecular composition and distribution, its label-free approach and complex data interpretation processes can limit its adoption in clinical and pharmaceutical research conducted by Contract Research Organizations (CROs). The lack of standardized protocols and the need for specialized expertise in MSI data analysis present challenges for CROs aiming to integrate MSI into their service offerings.
The requirement for specialized instrumentation and significant computational resources for MSI data analysis may deter CROs from investing in this technology. As a result, the potential of MSI to drive growth in the CRO mass spectroscopy services market may be constrained, despite its immense potential in clinical and pharmacological research. Strategies to overcome these limitations, such as standardization of protocols and the development of user-friendly data analysis software, will be crucial in unlocking the full potential of MSI and facilitating its adoption by CROs.
Opportunity: Advancement in Mass Spectrometry Imaging (MSI) techniques
These advancements in MSI techniques create significant opportunities for the CRO mass spectroscopy services market. CROs specializing in mass spectroscopy services stand to benefit from the growing demand for MSI in drug development and fundamental research. By offering MSI-based services tailored to the needs of pharmaceutical companies and research institutions, CROs can capitalize on this opportunity to expand their service portfolio and attract new clients, the integration of MSI into the drug discovery and development process enhances the efficiency and effectiveness of preclinical studies, ultimately accelerating the drug development timeline.
This increased adoption of MSI in drug research creates a favorable market environment for CROs offering mass spectroscopy services, positioning them for growth and success in the evolving landscape of pharmaceutical research and development.
The proteomics services segment has emerged as the cornerstone of the CRO mass spectroscopy services market share of 78% in 2023, revolutionizing protein analysis with mass spectrometry. At the heart of this innovation lies the Protein-Works services, offering comprehensive support across multiple workflows in the biological sciences. These services encompass critical tasks such as protein identification, confirmation of protein sequences, determination of protein molecular weights, and complex sample profiling.
Proteomics services utilize advanced techniques and methodologies to analyze proteins comprehensively. These services can be tailored to analyze a single protein or to conduct large-scale analysis of specific proteomes, including protein abundances, modifications, interactions, and compound associations. Key to this capability are two primary mass spectrometry systems: nano LC-MS/MS and MALDI TOF/TOF. These systems enable peptide mapping, protein identification, and analysis of post-translational modifications, empowering researchers with unparalleled insights into protein function and regulation.
In a rapidly evolving landscape of biological sciences, Proteomics services continue to drive innovation and unlock new possibilities in protein analysis. By leveraging advanced mass spectrometry techniques and expertise, Proteomics services play a pivotal role in advancing research and development efforts across various industries. As the demand for precise and comprehensive protein analysis grows, proteomics services are poised to remain at the forefront of the CRO mass spectroscopy services market, driving continued growth and innovation in the field.
The pharmaceutical & biopharmaceutical companies segment, in 2023, stood as the largest contributor to the CRO mass spectroscopy services market. Mass spectrometry (MS) has emerged as a pivotal technology across various application domains, with its importance steadily increasing in recent years. In pharmaceutical analysis, MS plays a crucial role due to the stringent regulatory procedures, adherence to good laboratory/manufacturing practices, and the necessity for numerous routine quality control analyses.
Throughout the drug development cycle, the role of MS varies significantly. It takes center stage during the drug discovery and development phase, where its capabilities are paramount in elucidating molecular structures, identifying potential drug candidates, and analyzing complex biomolecules. However, in routine quality control, the role of MS is more subdued, serving indispensable functions for selected applications where precision and accuracy are paramount.
As pharmaceutical and biopharmaceutical companies continue to drive innovation and development in the healthcare industry, the demand for CRO mass spectroscopy services is expected to rise correspondingly. By providing specialized expertise and state-of-the-art instrumentation, CROs play a vital role in supporting the diverse analytical needs of pharmaceutical companies, contributing to advancements in drug discovery, development, and quality assurance. As such, the Pharmaceutical & biopharmaceutical companies segment remains a key driver of growth in the CRO mass spectroscopy services market, underscoring the indispensable role of MS in pharmaceutical analysis and development.
Segments Covered in the Report
Service Type
By End Use
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on CRO Mass Spectroscopy Services Market
5.1. COVID-19 Landscape: CRO Mass Spectroscopy Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global CRO Mass Spectroscopy Services Market, By Service Type
8.1. CRO Mass Spectroscopy Services Market, by Service Type, 2024-2033
8.1.1. Proteomics Services
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Metabolomics Services
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global CRO Mass Spectroscopy Services Market, By End Use
9.1. CRO Mass Spectroscopy Services Market, by End Use, 2024-2033
9.1.1. Pharmaceutical & Biopharmaceutical Companies
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Medical Device Companies
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global CRO Mass Spectroscopy Services Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.1.2. Market Revenue and Forecast, by End Use (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.1.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.1.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.2.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.2.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.2.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.2.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.2.6.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.3.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.3.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.3.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.3.6.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.4.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.4.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.4.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.4.6.2. Market Revenue and Forecast, by End Use (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.5.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Service Type (2021-2033)
10.5.4.2. Market Revenue and Forecast, by End Use (2021-2033)
Chapter 11. Company Profiles
11.1. Alturas Analytics Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. BGI Group
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Charles River Laboratories International Inc
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Creative Proteomics
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Evotec SE
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Inotiv Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Bioanalytical Systems Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Labcorp Drug Development
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. MtoZ-Biolabs Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. PPD Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client